Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.60 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.60 |
| ▸ | GRM5 | P41594 | 11/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7845539 | 0.91 | PDE10A (0.53) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL171489 | 0.87 | PDE10A (0.46) | PDE10AGRM1GRM5NAMPT | |
| SCHEMBL30308912 | 0.86 | GRM1 (0.64) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL7837563 | 0.85 | GRM1 (0.59) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL29591544 | 0.85 | GRM1 (0.59) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL7836976 | 0.84 | GRM1 (0.51) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL24165372 | 0.83 | GRM1 (0.53) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL30648008 | 0.83 | GRM1 (0.53) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL23015101 | 0.82 | GRM1 (0.57) | PDE10AGRM1GRM5PDK4NAMPT | |
| SCHEMBL25480230 | 0.81 | GRM1 (0.59) | PDE10AGRM1GRM5PDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1083178-B1 | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030109516-A1 | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | PFIZER INC. | 2003-06-12 | — | — | US | disclosed |
| US-6521630-B1 | Serotonin reuptake inhibitors; treatment of diseases, conditions or disorders of the central nervous system | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-6303627-B1 | FOR THERAPY OF PHYSIOLOGICAL AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| EP-1083178-A1 | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999065487-A1 | INHIBITORS OF SEROTONIN REUPTAKE | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0965587-A1 | Tetrahydropyridinyl- and piperidinyl Inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109516-A1 | Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof | HTR2C, HTR1F, HTR3C | PDE10A 2489/4885GRM1 82/4885GRM5 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.